In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with 20+ CEO and C-suite leaders from the CDMO ecosystem, exploring two simple questions that reveal what’s really happening inside the building:
What’s the biggest internal business challenge for the year ahead?
And what’s the biggest opportunity inside their business in 2026?
Your host, Raman Sehgal, brings together a punchy set of operator insights spanning commercial readiness, capacity decisions, flawless execution, commercial excellence, and the shift toward deeper partnerships and integrated models.
Show features insights from:
Ankit Gupta, CEO, InstaPillNick Fortin, CEO, CodisEric Edwards, MD, PhD, CEO, Phlow USAJason Anderson, CEO, enseraDirk T. Lange, CEO, Pyramid Pharma ServicesPhilip Macnabb, CEO, CuriaMatthew Bio, CSO, Cambrex and President, Snapdragon ChemistryBruce Thompson, CTO, Kincell BioBill Vincent, Biotech Entrepreneur, CEO and Board MemberDerek Hennecke, Founder, Investor and Board MemberStephen Dilly, CEO, Sonoma BiotherapeuticsElisabeth Stampa, CEO, Medichem SLChristiane Bardroff, COO LeaderKaan-Fabian Kekec, Partner, Simon-Kucher Healthcare and Life SciencesIan Tzeng, Managing Director, L.E.K. ConsultingAdam Siebert, Managing Director, L.E.K. ConsultingJ.D. Mowery, President, CDMO Division, Bora PharmaceuticalsJon Alberdi, CEO, VivebiotechPeter Belden, President, US, TjoapackMolecule to Market is also sponsored by Bora Pharmaceuticals, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!